Baseline patient characteristics
| Mel-CTLA4-A | Mel-CTLA4-B | Mel-PD1-A | Mel-PD1-B | NSCLC-PD1 | |
| Total, n | 10 | 29 | 29 | 36 | 56 |
| Age, median (range) | 59.3 (26 to 79) | 58.3 (35 to 86) | 64.0 (39 to 84) | 61.6 (31 to 83) | 63.1 (35 to 81) |
| Gender, n | |||||
| Male | 4 | 13 | 16 | 21 | 36 |
| Female | 6 | 16 | 13 | 15 | 20 |
| Primary tumor, n | |||||
| Melanoma | 10 | 29 | 29 | 36 | 0 |
| NSCLC | 0 | 0 | 0 | 0 | 56 |
| Adenocarcinoma | 0 | 0 | 0 | 0 | 37 |
| SCC | 0 | 0 | 0 | 0 | 17 |
| Large cell carcinoma | 0 | 0 | 0 | 0 | 2 |
| Treatment regimen, n | |||||
| Anti-PD-1 | 0 | 0 | 29 | 36 | 56 |
| Nivolumab | 0 | 0 | 1 | 14 | 50 |
| Pembrolizumab | 0 | 0 | 28 | 22 | 6 |
| Anti-CTLA-4 | |||||
| Ipilimumab | 10 | 29 | 0 | 0 | 0 |
| Prior therapy lines, n (%) | |||||
| 0 | 4 (40%) | – | 20 (69%) | 30 (83%) | 1 (2%) |
| 1 | 4 (40%) | – | 9 (31%) | 6 (17%) | 46 (82%) |
| 2 | 2 (20%) | – | 0 (0%) | 0 (0%) | 7 (12%) |
| >2 | 0 (0%) | – | 0 (0%) | 0 (0%) | 2 (4%) |
| Prior immunotherapy, n | |||||
| No | 10 | 29 | 29 | 36 | 56 |
| Yes | 0 | 0 | 0 | 0 | 0 |
| Cerebral metastasis, n (%) | |||||
| No | 6 (60%) | – | 17 (59%) | 15 (42%) | 0 (0%) |
| Yes | 2 (20%) | – | 11 (38%) | 2 (5%) | 0 (0%) |
| Unknown | 2 (20%) | – | 1 (3%) | 19 (53%) | 56 (100%) |
| LDH (U/L), median (range) | 207 (168 to 247) | 369 (283 to 881) | 229 (124 to 359) | 315 (128 to 1523) | 269 (133 to 860) |
All patients received immune checkpoint inhibitor monotherapy and did not receive any prior line of immunotherapy.
LDH, lactate dehydrogenase; NSCLC, non-small cell lung cancer; PD-1, programmed cell death 1; SCC, squamous cell carcinoma.